Exenatide injectable + Insulin glargine-lixisenatide

MediHelp rates the interaction as major. Exenatide injectable and Insulin glargine-lixisenatide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both products are GLP-1 receptor agonists (lixisenatide in the fixed-dose combination and exenatide), so combining them duplicates therapy without a proven added benefit. Gastrointestinal adverse effects, and hypoglycemia from the insulin component, may be increased.

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid using two GLP-1 receptor agonists together; choose a single agent and stop the duplicate. If the combination is unavoidable, monitor blood glucose and GI tolerability closely and reduce insulin as needed.

MediHelp also lists interactions of Insulin glargine-lixisenatide with, for example, Albiglutide, Chlorpropamide, Dulaglutide. The full list is on the Insulin glargine-lixisenatide page.